EUCTR2013-001804-12-NL进行中（未招募）1 期
A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101) at different doses with or without interferon alpha as combination therapy with carboplatin and paclitaxel in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options. - CervISA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1) Women = 18 years of age.
- •2) Cervical cancer confirmed by histology.
- •3) Advanced (Stage IIIb/IVa with para-aortic lymph nodes involvement beyond the renal vein) or, metastatic (Stage IVb ) or recurrent cervical cancer confirmed by clinical and/or radiological proof with no curative treatment options.
- •4) Tumour must be HPV16 positive (to be determined on archival tumour tissue (=10 years old); if that is not available a pre-treatment biopsy will be required).
- •5) Patients should be eligible for chemotherapy with carboplatin and paclitaxel.
- •6) Performance status (WHO scale/ECOG) = 1.
- •7) Written informed consent according to local guidelines.
- •8) Written approval by the treating physician / investigator of his/her clinical judgement that the patient has a reasonable life expectancy and is sufficiently fit and motivated to complete the study treatment and comply to all study procedures specified by the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1) Prior treatment with anti-HPV agents.
- •2) Chronic systemic steroid use. Local application (i.e. stable doses of topical or inhaled corticosteroids) is allowed.
- •3) Less than 4 weeks since the last treatment with other cancer therapies, (i.e. endocrine therapy, immunotherapy, radiotherapy, chemotherapy, etc), less than 8 weeks for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C.
- •4) Toxicities resulting from previous anti-cancer therapy (radiation, chemotherapy or surgery) must be resolved to = grade 2 as defined by CTCAE version 4.0.
- •5) Recent treatment (within 30 days of first study treatment) with another investigational drug.
- •Haematology and biochemistry:
- •6) Inadequate bone marrow function: Absolute Neutrophil Count (ANC) < 1.5 x 109/L, or platelet count < 100 x 109/L or hemoglobin < 6 mmol/L.
- •7) Inadequate liver function, defined as:
- •Serum (total) bilirubin > 2 x upper normal limit (ULN); or
- •ASAT or ALAT > 2.5 x ULN (> 5 x ULN in patients with liver metastases); or
- •Alkaline phosphatase levels > 2.5 x ULN (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
- •8) Clinical suspicion or radiological evidence of brain or leptomeningeal metastases. A CT/MRI scan should be performed if there is any clinical evidence of brain metastases.
- •9) Previous or current malignancies at other sites, with the exception of basal or squamous cell carcinoma of the skin and with the exception of other malignancies from which the patient may be considered cured as evidenced by complete regression of all lesions >10 years ago.
- •10) Active HIV, chronic hepatitis B or C infection.
- •11) Patients of childbearing potential (defined as < 2 years after last menstruation and having an intact reproductive system), who are not on oral contraceptives or do not use effective means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).
- •12) Pregnancy or lactation. Serum pregnancy test to be performed within 7 days prior to study treatment start in patients of childbearing potential.
- •13) Major surgical procedure within 28 days prior to the first study treatment.
- •14) Uncontrolled sustained hypertension (systolic > 180 mm Hg and/or diastolic > 110mm Hg).
- •15) Clinically significant (i.e. active) cardiovascular disease defined as:
- •Stroke within = 6 months prior to day 1;
- •Transient Ischemic Attack (TIA) within = 6 months prior to day 1;
- •Myocardial infarction within = 6 months prior to day 1;
- •Unstable angina;
- •New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure (CHF);
- •Serious cardiac arrhythmia requiring medication;
- •16) History of severe bronchial asthma and/or severe allergy.
- •17) Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, auto-immune diseases) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
研究者
相似试验
进行中（未招募）
1 期
An experimental study in women with cervical cancer to test the safety and activation of the patient's own immune system after treatment with chemotherapy in combination with a vaccine directed against an infection with Human Papilloma Virus Type 16 (HPV16).Patients with advanced (Stage IIIb-IVa with involvement of lymph nodes beyond the renal vein) or metastatic (stage IVb )or recurrent HPV16 positive cervical cancer for whom no curative treatment options existMedDRA version: 19.0 Level: LLT Classification code 10008229 Term: Cervical cancer System Organ Class: 100000004864EUCTR2013-001804-12-BEISA Therapeutics B.V.90
已完成
不适用
A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101/ISA101b) immunotherapy in combination with standard of care therapy (carboplatin and paclitaxel with or without bevacizumab) in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options.cervical canceradvanced or recurrent cervical cancer10038594NL-OMON45132ISA Therapeutics B.V.50
进行中（未招募）
1 期
An experimental study in women with cervical cancer to test the safety and activation of the patient's own immune system after treatment with chemotherapy in combination with a vaccine directed against an infection with Human Papilloma Virus Type 16 (HPV16).Patients with advanced (Stage IIIb-IVa with involvement of lymph nodes beyond the renal vein) or metastatic (stage IVb) or recurrent HPV16 positive cervical cancer for whom no curative treatment options existMedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000020977EUCTR2013-001804-12-DEISA Therapeutics B.V.100
进行中（未招募）
1 期
A clinical study to determine the safety, pharmacokinetics and efficacy of GMI-1271 when given at the same time as anti-cancer drugs in patients with a rare type of cancer called acute myeloid leukemia.Acute myeloid leukemiaMedDRA version: 20.0Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002448-42-IEGlycoMimetics, Inc.102
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.EUCTR2009-011925-14-ATBoehringer Ingelheim RCV GmbH & Co. KG132